November 2, 2017 / 9:16 PM / 18 days ago

BRIEF-Oncomed posts Q3 loss per share $0.28

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc

* Oncomed announces third quarter 2017 financial results and operational highlights

* Q3 loss per share $0.28

* Q3 revenue $5.1 million versus $5.9 million

* Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​

* Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​

* Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below